Lubetzki C
Fédération de Neurologie, INSERM U-495, Hôpital de la Salpêtrière, 75013 Paris.
Rev Neurol (Paris). 2001 Sep;157(8-9 Pt 2):996-1000.
Disease-modifying treatments in multiple sclerosis emerged during the last few years, concerning mainly relapsing-remitting forms of the disease. They are essentially represented by beta-interferons. beta-interferons reduce relapse rate, achieving about 30 p. cent, and have an effect on brain lesions detected on MRI. They are indicated for use in ambulatory patients with relapsing-remitting multiple sclerosis characterized by at least 2 attacks of neurological dysfunction over the preceding 2 (or 3)-year period. Questions and controversies still remain concerning dose-response effect, early initiation and duration of treatment. Copolymer, which has a different mechanism of action, also decreases frequency of relapses, and the magnitude of the clinical effect is similar to beta-interferon. Copolymer is indicated for use in patients with relapsing-remitting multiple sclerosis, having either an intolerance or a contra-indication to beta-interferon.
近年来出现了针对多发性硬化症的疾病修正治疗方法，主要针对复发缓解型疾病。它们主要由β-干扰素代表。β-干扰素可降低复发率，达到约30%，并对MRI检测到的脑部病变有作用。它们适用于在前2（或3）年期间至少有2次神经功能障碍发作的复发缓解型多发性硬化症门诊患者。关于剂量反应效应、早期启动和治疗持续时间仍存在问题和争议。作用机制不同的共聚物也可降低复发频率，临床效果的程度与β-干扰素相似。共聚物适用于对β-干扰素不耐受或有禁忌的复发缓解型多发性硬化症患者。
